Table 3.
Characteristics of FOLFIRI treatment.
| Time on FOLFIRI (months) | |
| Median | 8 |
| Range | 1–61 |
|
| |
| Protocol modification | |
| Dose reduction (75%) | 4/18% |
| Interval prolongation (qd21) | 2/9% |
|
| |
| Adverse events (no./%) | |
| Peripheral neuropathy | 21/95% |
| Peripheral neuropathy > grade 2 | 1/5% |
| Nausea and vomiting | 16/73% |
| Nausea and vomiting > grade 2 | 0/0% |
| Diarrhea | 5/23% |
| Diarrhea > grade 2 | 0/0% |
| Neutropenia | 11/50% |
| Neutropenia > grade 2 | 3/14% |
| Thrombocytopenia | 1/5% |
| Thrombocytopenia > grade 2 | 0/0% |
| Anemia | 3/14% |
| Anemia > grade 2 | 0/0% |
|
| |
| Treatment after disease progress (no./%) | |
| Gemcitabine/NAB-paclitaxel | 14/64% |
| Gemcitabine/erlotinib | 1/5% |
| FOLFIRINOX re-escalation | 3/14% |
| Best supportive care | 4/18% |